Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration

Author(s):

Angeles Alvarez Secord, MD, MHSc ,Dana M. Chase, MD, FACOG

Panelists discuss recent data on various antibody-drug conjugates (ADCs) in ovarian cancer, including mirvetuximab soravtansine from trials like FORWARD II, MIRASOL, and PICCOLO; luveltamab tazevibulin and rinatabart sesutecan from STRO-002-GM1 and REFRαME-O1; and raludotatug deruxtecan from REJOICE-Ovarian01, highlighting the evolving role of these agents in the treatment landscape for ovarian cancer.

EP: 1.Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer

EP: 2.Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer

EP: 3.Duration of PARP Inhibitor Maintenance Therapy for Ovarian Cancer

EP: 4.Emerging Combinations in Maintenance Therapy for Ovarian Cancer

EP: 5.Optimizing Ovarian Cancer Care: PARP Resistance, Management of Oligoprogression, and Adverse Event Mitigation

EP: 6.Use of Trastuzumab Deruxtecan in Ovarian Cancer

Now Viewing

EP: 7.Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration

EP: 8.Navigating Treatment Strategies for Advanced Cervical Cancer: Localized Therapy, KEYNOTE-A18 Trial Data, and Frontline Approaches

Video content above is prompted by the following:

Briefly comment on recent data surrounding other antibody-drug conjugates in ovarian cancer and discuss the evolving role of these agents in the treatment landscape.
Mirvetuximab soravtansine (anti-FR)
FORWARD II; MIRASOL; PICCOLO
Luveltamab tazevibulin (anti-FR), rinatabart sesutecan (Rina-S)
STRO-002-GM1; REFRαME-O1
Rina-S
Raludotatug deruxtecan (R-DXd, anti-CDH6)
REJOICE-Ovarian01